The progression of cancers from primary tumors to invasive and metastatic stages accounts for the overwhelming majority of cancer deaths. Understanding the molecular events which promote metastasis is thus critical in the clinic. Translational control is emerging as an important factor in tumorigenesis. The messenger RNA (mRNA) cap-binding protein eIF4E is an oncoprotein that has an important role in cancer initiation and progression. eIF4E must be phosphorylated to promote tumor development. However, the role of eIF4E phosphorylation in metastasis is not known. Here, we show that mice in which eukaryotic translation initiation factor 4E (eIF4E) cannot be phosphorylated are resistant to lung metastases in a mammary tumor model, and that cells isolated from these mice exhibit impaired invasion. We also demonstrate that transforming growth factor-beta (TGFβ) induces eIF4E phosphorylation to promote the translation of Snail and Mmp-3 mRNAs, and the induction of epithelial-to-mesenchymal transition (EMT). Furthermore, we describe a new model wherein EMT induced by TGFβ requires translational activation via the non-canonical TGFβ signaling branch acting through eIF4E phosphorylation.
INTRODUCTION
The eukaryotic translation initiation factor 4E (eIF4E) binds to the messenger RNA (mRNA) 5ʹ cap structure (m7GpppN, where N is any nucleotide, and m is a methyl group), and facilitates mRNA recruitment to the ribosome. eIF4E is a subunit of the eIF4F complex, which also contains eIF4A, an RNA helicase and eIF4G, a scaffolding protein, which bridges the mRNA and the ribosome. 1 In most circumstances, the formation of the eIF4F complex is ratelimiting and is dependent on the eIF4E availability, as it is the least abundant of all the initiation factors.
2,3 eIF4E availability is controlled by its inhibitors, the eIF4E binding proteins, 4, 5 and its activity is also regulated by phosphorylation on serine 209 by the Map Kinase Integrating Kinases (MNK1/2), downstream of both the MAPK/ERK kinase/extracellular-signal-regulated kinase and p38 Map Kinase pathways. [6] [7] [8] Phosphorylation of eIF4E requires prior docking of MNKs to the scaffolding protein eIF4G, 9 indicating that eIF4E phosphorylation occurs after the formation of the eIF4F complex.
eIF4E promotes neoplastic transformation and tumorigenesis in numerous cell-based and animal models. [10] [11] [12] Consistent with this activity, eIF4E is overexpressed in a wide variety of human cancers (reviewed in Mamane et al. 13 ). Consequently, there is currently much interest in its potential as a therapeutic target. [14] [15] [16] The cancer promoting activity of eIF4E is dependent on its phosphorylation, as overexpression of a phosphorylation-deficient mutant (eIF4E S209A ) fails to promote tumorigenicity. 12, 17 Moreover, inhibiting MNKs impairs xenograft growth, and mice lacking MNKs are resistant to cancer in the Lck-Pten lymphoma model. 18, 19 eIF4E promotes metastasis in various mouse models, 20, 21 and is associated with poor prognosis in several types of cancer. 22, 23 We have previously shown that mice bearing the eIF4E S209A mutation are resistant to prostate cancer development and that mouse embryonic fibroblasts (MEFs) isolated from these mice are resistant to neoplastic transformation. 24 Interestingly, eIF4E
S209A
MEFs displayed impaired anchorage independent growth, consistent with a reduced metastatic potential. 25 Furthermore, certain pro-metastatic factors were identified in this study as being controlled by phospho-eIF4E, notably the matrix metalloproteinases MMP-3 and MMP-9. 24 MMPs cleave several component proteins of the extracellular matrix to promote migration and invasion 26 and induce epithelial-to-mesenchymal transition (EMT). 27 These observations point to a role for eIF4E phosphorylation in metastasis, but experimental evidence for this link is lacking.
Here, we investigate the role of eIF4E phosphorylation in metastasis. We demonstrate that phosphorylation of eIF4E promotes invasion in transformed MEFs, as well as transforming growth factor-beta (TGFβ)-induced EMT in normal epithelial cells. We identify mRNAs regulated by eIF4E phosphorylation, which can mediate its pro-metastatic effects, including Snail and Mmp-3. Importantly, we validate our findings in vivo using a metastatic mouse mammary tumor model. Taken together, these results demonstrate that eIF4E phosphorylation is a key event in the metastatic process.
RESULTS

eIF4E phosphorylation promotes migration and invasion
To explore whether eIF4E phosphorylation has a role in metastasis, we utilized a cell model that we had previously developed. 24 MEFs were derived from mice bearing the eIF4E S209A mutation and their wild-type (WT) counterparts, and transformed with c-MYC and H-RAS V12 . These transformed WT and eIF4E S209A MEFs display similar proliferation, cell cycle progression and levels of apoptosis, yet eIF4E S209A MEFs possess reduced tumorigenic potential. 24 We chose to use this model as it is not dependent on overexpression, and avoids targeting the MNKs, which phosphorylate additional proteins such as Sprouty2, 28 cPLA2 29 and hnRNPA1. 30, 31 We compared these MEFs in assays that measure metastatic potential: anchorage independent growth, 25 random migration, 32 transwell invasion 33 and colony outgrowth in matrigel. 34 As previously reported, 24 eIF4E S209A MEFs formed twofold fewer colonies when plated in agarose (Figure 1a ). This effect was specific to eIF4E phosphorylation as treatment with the MNK inhibitor CGP57380 reduced colony formation in the WT MEFs in a dose-dependent manner, whereas eIF4E S209A MEFs remained insensitive to this treatment ( Figure 1a) . Phosphorylation of eIF4E also promotes migration, as eIF4E S209A MEFs displayed~20% reduction in random migration speeds, as seen by time-lapse microscopy ( Figure 1b) . Accordingly, these cells traveled shorter distances than their WT counterparts ( Figure 1c ). Strikingly, invasion was severely impaired in eIF4E S209A MEFs, as their invasion index was reduced by fivefold in a transwell invasion assay (Figure 1d ). Corroborating these findings, in a matrigel colony outgrowth assay, colonies of WT MEFs exhibited a branched morphology, indicative of their invasion into the basement membrane matrix, while eIF4E S209A colonies remained spherical (Figure 1e ). Thus, eIF4E phosphorylation promotes in vitro characteristics that correlate with metastatic potential, prompting further investigation into its role in metastasis.
Phosphorylated eIF4E promotes the translation of metastasis-related mRNAs To study the mechanism by which eIF4E phosphorylation favors pro-metastatic characteristics, the expression levels of the Y-boxbinding protein 1 (YB1) were assessed in WT and eIF4E S209A MEFs. This protein was previously identified as having an important role in eIF4E-mediated invasion. 35 However, YB1 levels did not vary between the two cell lines (Supplementary Figure S1) , suggesting that this protein is not responsible for the invasion differences in this model. To identify candidate factors that promote the prometastatic phenotype of WT MEFs, pathway analysis was performed on a previously generated dataset of mRNAs translationally regulated by eIF4E phosphorylation. 24 Pathways significantly increased in WT cells were identified and clustered using the DAVID functional annotation database. 36, 37 Enriched clusters included potentially metastasis-related functions, such as chemotaxis, proteases and immune signaling, as well as a general cancer cluster and one corresponding to glutathione metabolism (Figure 2a) . Clusters corresponding to plasma membrane proteins, carbohydrate-binding proteins, leucine-rich repeat-containing proteins and zinc-binding proteins were also identified. The full list of clusters generated by DAVID and the mRNAs grouped in each cluster are presented in Supplementary Figures S2 and S3 . To validate these findings and further investigate pro-metastatic mRNAs regulated by eIF4E phosphorylation, polysome profile analysis was performed on transformed WT and eIF4E S209A MEFs serum-stimulated for 2 h. Quantitative reverse transcription-PCR was used to monitor the distribution across a sucrose density gradient of mRNAs chosen for their relevance to invasion and metastasis, or because they were identified in the clustering analysis. There was no significant difference in global translation between WT and eIF4E S209A MEFs, as the polysome profiles were nearly identical (Figure 2b) . Accordingly, the distributions of housekeeping mRNAs β-actin and GAPDH across the sucrose density gradient were similar (Figures 2c and d) . In contrast, the mRNA encoding MMP-3, which had been previously identified as being sensitive to eIF4E phosphorylation 24 was significantly shifted toward light polysomes in eIF4E S209A MEFs (Figure 2e ). This is indicative of regulation of translation initiation by eIF4E phosphorylation. Similarly, the polysomal distribution of Snail mRNA, an important transcription factor in the induction of EMT, 38 was also significantly shifted toward light polysomes in eIF4E S209A MEFs (Figure 2f ). However, no differences were detected for other factors tested including the EMT marker vimentin, the EMT-related transcription factor TWIST, the metalloproteinase MMP-14 and the vascular endothelial growth factor member C (Supplementary Figure S4) . Our results indicate that eIF4E phosphorylation promotes the translation of mRNAs encoding regulators of EMT and invasion such as SNAIL and MMP-3.
In keeping with the translational repression of Snail and Mmp-3 in eIF4E S209A MEFs, the expression of SNAIL and MMP-3 protein was also repressed in these cells (Figure 3a and Supplementary Figure S1 ). Next, it was pertinent to demonstrate that SNAIL and MMP-3 are responsible for phospho-eIF4E's pro-metastatic properties. To this end, we restored SNAIL and MMP-3 levels in eIF4E
S209A
MEFs by overexpressing eIF4E
WT or by overexpressing either Snail or Mmp-3 mRNAs lacking their regulatory 5ʹ and 3ʹ untranslated regions (Figure 3a) . With either strategy, restoration of SNAIL and MMP-3 levels rescued invasion, whereas overexpression of eIF4E S209A failed to do so ( Figure 3b ). These experiments demonstrate that SNAIL and MMP-3 mediate the pro-invasive properties of phosphorylated eIF4E. eIF4E is phosphorylated during TGFβ-induced EMT SNAIL and MMP-3 are important factors promoting cell invasiveness, metastasis and EMT, 27 ,38 therefore we investigated whether eIF4E phosphorylation could have a role in EMT. Since transformed WT and eIF4E S209A MEFs are inadequate for studying EMT, we employed the well-studied normal murine mammary gland (NMuMG) cell model of TGFβ-induced EMT. 39 Treatment with TGFβ engendered a strong increase in eIF4E phosphorylation in a time dependent manner (Figure 4a ). Increased phospho-eIF4E levels were accompanied by an increase in the mesenchymal markers N-cadherin, fibronectin and vimentin, as well as a decrease in the epithelial marker, E-cadherin (for a review on EMT markers, see Zeisberg and Neilson 40 ) . Ostensibly, TGFβ controls the phosphorylation of eIF4E via non-canonical signaling leading to p38 and MAPK activation. 41 Indeed, the phosphorylation and activation of MNK1 was preceded by that of its upstream kinases, p38 and extracellular-signal-regulated kinase (ERK) (Figure 4b ). In addition, chemical inhibition of ERK or p38, using U0126 or SB203580, respectively, reduced TGFβ-stimulated phosphorylation of eIF4E (Figure 4c ), which was abrogated by a combination of both inhibitors (Figure 4c ). NMuMG cells engineered to express a dominant-negative mutant of p38 (p38AGF) or MKK3 (MKK3AL) are defective in undergoing a TGFβ-induced EMT. 42 TGFβ failed to stimulate phosphorylation of eIF4E when p38 activation was blocked in p38AGF-and MKK3AL-NMuMG cell lines, consistent with non-canonical TGFβ signaling impinging on eIF4E (Figure 4d ). TGFβ-induced eIF4E phosphorylation was dependent on the TGFβ receptor kinase activity because SB431542, an inhibitor of the TGFβ receptor kinase, 43 blocked eIF4E phosphorylation (Figure 4e ). Taken together, these results demonstrate that the activation of TGFβ signaling, which is frequently dysregulated in breast cancer, 44 induces eIF4E phosphorylation, and that elevated phospho-eIF4E correlates with TGFβ-induced EMT.
Phospho-eIF4E, EMT and metastasis N Robichaud et al eIF4E phosphorylation promotes TGFβ-induced EMT To determine whether eIF4E phosphorylation is a driver or a sideeffect of EMT induction, we used a chemical inhibitor of the MNKs, CGP57380. 45 Treatment with this inhibitor blocked TGFβ-stimulated eIF4E phosphorylation and SNAIL expression (Figure 5a ), without affecting Snail mRNA levels (Supplementary Figure S5) . Importantly, CGP57380 abrogated the molecular and morphological changes associated with EMT. Specifically, this inhibitor blocked the upregulation of the mesenchymal markers vimentin, fibronectin and N-cadherin by TGFβ (Figure 5a Figure S6 ). The effect of pharmacologically targeting MNK activity on TGFβ-stimulated EMT was not due to inhibition of the Smad2 transcriptional pathway, since TGFβ treatment resulted in comparable phosphorylation of Smad2 in the presence or absence of CGP57380 ( Figure 5a ). To provide further evidence for the role of eIF4E phosphorylation in EMT, we knocked down MNK1 by smallinterfering RNA (siRNA). MNK1 was targeted because it is the isoform that responds to MAPK signaling, while MNK2 is relatively insensitive to upstream signaling and maintains a basal level of activation. 46 Knock down of MNK1 prevented TGFβ-stimulated eIF4E phosphorylation as well as the TGFβ-induced expression of Figure S5) . Consistent with experiments performed using MEFs, YB1 levels were unaffected by eIF4E phosphorylation in NMuMG cells (Figures 5a and b) . Considering that the MNKs have targets other than eIF4E, we performed a knockdown/add-back experiment to investigate the impact of phospho-eIF4E on EMT in a MNK-independent model. Phospho-eIF4E, EMT and metastasis N Robichaud et al
We stably expressed either eIF4E WT or eIF4E S209A in MCF10A cells, followed by short-hairpin RNA silencing of the endogenous eIF4E. The short-hairpin RNA was specific to the human eIF4E and therefore did not inhibit expression of the exogenous murine eIF4E (Figure 5c ). Knockdown of eIF4E impaired SNAIL expression and blocked TGFβ-mediated EMT, as indicated by reduced induction of vimentin and fibronectin (Figure 5c ). Strikingly, when endogenous eIF4E was knocked down, only eIF4E
WT but not eIF4E S209A rescued SNAIL, vimentin and fibronectin expression (Figure 5c ). Importantly, only cells expressing eIF4E WT , either the endogenous or exogenous form, expressed appreciable levels of SNAIL, vimentin and fibronectin (Figure 5c ). In contrast, cells expressing the S209A mutant form of eIF4E had low amounts of the latter EMT markers, similarly to cells expressing low levels of eIF4E (Figure 5c ). The effects we observe in the MCF10A model system indicate that defects in the MNK/eIF4E axis do not impinge upon canonical TGFβ signaling, since TGFβ-induced phosphorylation of Smad2 remained unchanged under all experimental conditions (Figure 5c ). Thus, these experiments demonstrate a critical role for translational control by phosphorylated eIF4E in TGFβ-induced EMT. eIF4E phosphorylation correlates with EMT and invasion in vivo We validated our findings in vivo in a widely used model to study EMT and metastasis. This model consists of a series of isogenic mammary cancer cell lines (67NR, 168FARN and 4T07) that are progressively more aggressive and present an increasingly mesenchymal phenotype. 47 Specifically, when inoculated into the mouse mammary fat pad, the 67NR cell line forms only noninvasive primary tumors; 168FARN cells are locally invasive and detectable in the lymph node, while the 4T07 cells metastasize to the lung. In mammary tumors formed by these cell lines, increased MNK1 activation and eIF4E phosphorylation coincided with the acquisition of invasive properties and with the expression of SNAIL, as this protein was low in 67NR tumors, but increased in locally invasive 168FARN and metastatic 4T07 tumors (Supplementary Figure S7) . The correlation between SNAIL expression, eIF4E phosphorylation and the acquisition of invasive properties of these cells, in vivo, provides further evidence for the importance of eIF4E phosphorylation in the metastatic process.
eIF4E phosphorylation promotes tumor onset and metastasis in PyMT mammary tumor model To assess the role of eIF4E phosphorylation in metastatic progression using a genetic model, eIF4E S209A mice were crossed with MMTV-PyMT mice. In this mammary tumor model, tumors metastasize to the lungs with 100% penetrance.
48 eIF4E S209A -PyMT mice exhibited a significant delay in tumor onset, developing palpable tumors on average 2 weeks later than their WT counterparts (Figure 6a ), confirming the importance of eIF4E phosphorylation in tumorigenesis. 24 The penetrance of mammary tumor development was also reduced in eIF4E S209A -PyMT mice, as~10% percent remained tumor-free. Nonetheless, once established, both WT and eIF4E S209A tumors grew at similar rates (Figure 6b ). End-point tumors displayed similar proliferation, as evaluated by ki67 staining of tumor sections (Figure 6c) , and Phospho-eIF4E, EMT and metastasis N Robichaud et al similar apoptosis, as measured by caspase 3 activation (Figure 6d) . Importantly, the metastatic potential of eIF4E S209A tumors was reduced, as eIF4E S209A -PyMT mice displayed a twofold reduction in lung metastases as compared with WT-PyMT mice (Figures 6e  and f) . Metastatic burden was assessed at equivalent tumor burden rather than at a defined age; it therefore does not reflect the late onset of eIF4E S209A tumors. Thus, eIF4E phosphorylation promotes the metastatic properties of eIF4E, in addition to its tumorigenic activity.
Based on our findings that eIF4E phosphorylation promotes the translation of mRNAs encoding SNAIL and MMP-3, we analyzed the expression of these factors by immunohistochemistry in tumor samples from PyMT-WT and PyMT-eIF4E S209A mice. Phosphorylation of eIF4E was elevated in WT tumors, as expected due to the activation of the MAPK pathway by the PyMT oncogene, 49 but remained undetectable in eIF4E S209A tumors (Figure 7a ). SNAIL and MMP-3 exhibited localized expression patterns in both WT and eIF4E S209A tumors (Figure 7a ). Indeed, as previously reported, these proteins were mainly expressed at tumor/stroma boundaries. 50, 51 Importantly, WT tumors displayed more extensive areas of SNAIL and MMP-3 expression (Figure 7a ), resulting in a higher percentage of SNAIL-and MMP-3-positive cells (Figures 7b  and c) . Taken together, these data support an important role for the phosphorylation of eIF4E in promoting invasion and metastasis through translational upregulation of its targets such as SNAIL and MMP-3. DISCUSSION eIF4E is an oncoprotein that is overexpressed in many human malignancies and its expression levels have been associated with poor survival in cancers of the breast, prostate, head and neck, pharynx, lung, bladder, liver, esophagus and stomach. 23, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] In one study on prostate cancer, the contribution of various factors dysregulating eIF4E has been investigated; eIF4E overexpression and the eIF4E binding protein 1 phosphorylation correlated with poor survival, whereas the eIF4E binding protein 1 overexpression exhibited inverse correlation. 23 In prostate cancer cell lines, targeting eIF4E using active site mammalian target of rapamycin inhibitors has been shown to inhibit the translation of prometastatic mRNAs such as YB1, vimentin, MTA1 and CD44. 35 For breast cancer, the most recent mechanistic insight into the role of eIF4E in vivo was obtained using the MMTV-PyMT model to show that eIF4E promotes the translation of vascular endothelial growth factor member A and MMP-9, 21 corroborating the observations obtained with human samples. [64] [65] [66] However, the role of eIF4E Phospho-eIF4E, EMT and metastasis N Robichaud et al phosphorylation in metastatic cancer has so far been overlooked. While eIF4E phosphorylation is known to be elevated in many human cancers 67 and has been reported in some cases to correlate with poor outcome, [68] [69] [70] [71] the role of phospho-eIF4E in metastasis is yet to be established.
Here, we show that eIF4E phosphorylation promotes metastatic progression, in addition to its role in tumor development. We provide mechanistic insight into the role of eIF4E phosphorylation in metastasis, by showing that phospho-eIF4E is required for the translation of Snail and Mmp-3 mRNAs, two factors that regulate EMT and invasion. Importantly, our investigation into the role of the MNK/eIF4E axis as an essential step during metastasis and TGFβ-induced EMT uncovered an unanticipated intersection of canonical and non-canonical TGFβ signaling to cooperatively promote EMT. We propose that a subset of mRNAs induced by canonical TGFβ signaling is better translated when eIF4E becomes phosphorylated via MNK1, which lies immediately downstream of the non-canonical TGFβ signaling pathway (see model, Figure 8 ).
MNK1 has been previously linked to TGFβ signaling and was reported to promote the translation of SMAD2. 72 However, no differences in the level of SMAD2 expression or activation were observed in our experiments. Cell differences aside, the decrease in SMAD2 mRNA upon MNK1 silencing observed by Grzmil et al. 72 occurred at 48 h. Furthermore, as stated in their paper, a corresponding decrease in SMAD2 protein upon MNK1 siRNA knockdown was only detected after 72 h. All of the experiments here were performed after MNK1 siRNA silencing for 24 h or less. These differences may explain the discrepancies between the two studies.
Our data demonstrate that eIF4E phosphorylation is important for EMT and invasion, which are early steps in metastatic progression. This raises the interesting possibility of using eIF4E phosphorylation as a biomarker for tumors at high risk of metastasizing. In support of this, several studies reported a correlation between high phospho-eIF4E levels and cancer progression and/or poor prognosis. [68] [69] [70] [71] However, it will be important to consider the levels of eIF4E phosphorylation in the context of total eIF4E expression, as well as expression and phosphorylation status of the the eIF4E binding proteins, as each of these markers can affect patient outcome, as seen in prostate cancer. 23 It would be important to explore the effects of reducing eIF4E phosphorylation at various stages of tumor progression. In particular, the dependency of tumors on eIF4E phosphorylation for invasion raises the possibility of its therapeutic targeting in metastatic cancer. Cercosporamide inhibits eIF4E phosphorylation and tumor growth in xenograft models, as well as the growth of metastatic lung colonies in a B16 experimental metastasis assay. 19 In this study, treatment with cercosporamide was initiated 24 h after injection of the B16 cells, after the initial colonization of the There are currently several inhibitors in clinical trials targeting eIF4E expression via antisense oligonucleotides, its availability through mammalian target of rapamycin inactivation or its recruitment to the eIF4F complex by blocking the eIF4E-eIF4G interaction. 16 However, the application of some of these inhibitors as well as currently used therapeutic agents such as rapamycin, 73 gemcitabine, 71 cytarabine 74 and herceptin 75 lead to increased eIF4E phosphorylation and concomitant resistance to treatment. Therefore, inhibitors of eIF4E phosphorylation may be useful in preventing resistance to some anticancer drugs, in addition to blocking metastatic progression.
Immunohistochemistry studies of tumor heterogeneity have identified phospho-eIF4E as one of the few biomarkers with high expression throughout the whole tumor sample (Ramón y Cajal). 76 In contrast most commonly studied signal transduction markers such as phospho-AKT, phospho-mammalian target of rapamycin and pMAPK displayed focal or 'patchy' expression in human breast cancers, indicating that large sections of most tumors would be unresponsive to inhibitors of these kinases. These findings further argue for the necessity of developing inhibitors of eIF4E phosphorylation for clinical use.
MATERIALS AND METHODS Reagents
TGFβ was purchased from PeproTech (Rocky Hill, NJ, USA). Insulin was from Sigma (St Louis, MO, USA). Scrambled control siRNA and MNK1-specific siRNAs were from IDT (Coralville, IA, USA).
Mice and tissue preparation eIF4E S209A mice 24 were bred with MMTV-PyMT. 48 Tumor onset in the mammary glands of control and experimental virgin mice was determined by palpation three times per week. Tumor growth was monitored by caliper measurements once per week or every 2 days near the experimental end point (single tumor above 2 cm 3 or total burden above Phospho-eIF4E, EMT and metastasis N Robichaud et al 6 cm 3 ), at which point lung and tumor samples were collected.
Step sections covering the entire lung were obtained and metastases were counted on all slides. The slide with the highest number of metastases was considered representative and used in further analyzes. Lung and tumor samples were fixed in 10% formalin for paraffin imbedding and sectioning at 6-μm thickness. Pulmonary metastases were counted on Hematoxylin and eosin-stained 50-μm step-sections. Serial sections of tumor samples were obtained for immunohistochemistry. Immunohistochemistry was performed using the Vectastain ABC peroxidase system (Vector Labs, Burlingame, CA, USA). All experiments involving animals were conducted in accordance with McGill University (Montreal, QC, Canada) animal care guidelines.
Cell lines 67NR, 168FARN and 4T07 cells were obtained from Fred Miller (Karmanos Institute, Detroit, MI, USA). Cells (5 × 10 5 ) were injected into each second mammary fat pad of BALB/c mice. Thirty days later, mice were killed and the primary tumor was harvested. Tumors obtained were immediately snap-frozen and pulverized under liquid nitrogen and stored at − 80°C until further use. Extracts were prepared by suspending the specimens in radioimmunoprecipitation assay lysis buffer 77 and used for immunoblotting.
Wild-type and eIF4ES209A-transformed MEFs were obtained as described. 24 For rescue experiments, MEFs were transfected with pcDNA3.1 constructs using lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) and selected with G418 sulfate. NMuMG epithelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, insulin, 2 mM glutamine, 100 U/ml penicillin and streptomycin. MCF10A cells were cultured in DMEM supplemented with 5% horse serum, hydrocortisone (0.5 μg/ml), insulin (10 μg/ml), epidermal growth factor (20 ng/ml), and penicillin--streptomycin (100 μg/ml each). NMuMG-BMN, NMuMG-HA-MKK3AL and NMuMG-Flag-p38AGF cells were kindly provided by A Bakin (Roswell Park Cancer Institute) and cultured in the same media as parental NMuMG cells. MCF10A stable cells expressing eIF4E or eIF4E S209A were infected with retrovirus produced in phoenix 293T cells, and subsequently selected with G418 sulfate and propagated. Cells were subsequently infected with lentiviral particles containing non-target control short-hairpin RNA or human eIF4E short-hairpin RNA (Sigma). siRNAs were introduced into NMuMG using RNAiMAX (Life Technologies) in accordance with the manufacturer's protocol.
Western blot analysis
Cell monolayers were washed with phosphate-buffered saline and harvested with trypsin. Washed cells were pelleted and lysed in radioimmunoprecipitation assay lysis buffer containing protease and phosphatase inhibitors (Roche, Basel, Switzerland). The lysate was cleared by centrifugation and protein concentration was determined with the BioRad protein concentration assay solution (Bio-Rad, Mississauga, ON, Canada). Protein (25-150 mg) were separated by 10-12% SDS--polyacrylamide gel electrophoresis and electroblotted onto a nitrocellulose membrane. Membranes were incubated overnight at 4°C with the indicated primary antibodies, and the following day incubated with the appropriate secondary anti-rabbit or anti-mouse antibodies for 1-3 h at room temperature. Membranes were developed with the enhanced chemiluminescence Western Blot Detection Kit. (ECL Western blotting Detection Reagents -GE Healthcare, Buckingham, UK.) Antibodies are described in the supplementary Table S1 .
Fluorescence microscopy Cells were cultured on glass coverslips in 12-well plates for 24 h, then fixed with ethanol:acetic acid at − 20°C, incubated with antibodies against the epithelial marker ZO-1 and then incubated with Alexa fluor 488 conjugated goat anti-rabbit IgG (Life Technologies). Nuclei were stained with Hoechst. The mounted samples were scanned with a Leica DM LB2 microscope (Leica microsystems, Wetzlar, Germany). Differences in ZO-1 immunofluorescence were quantified by selecting a defined area corresponding to edges between two cells and by calculating the imageJ parameter 'RawIntDen', which is the sum of the pixel values in the selected area.
Migration and invasion
Random migration was monitored by time-lapse microscopy and analyzed using MetaMorph Automation & Image Analysis Software (Molecular Devices, Sunnyvale, CA, USA); 30 000 cells were plated in matrigel-coated six-well plates and stimulated with 10% serum. Transwell migration assays were performed using 24-well cell culture inserts (BD Biosciences, Franklin Lakes, NJ, USA) as described. 78 Invasion index was obtained as the percentage of transwell migration with/without coating of the inserts with 50 μl 5% growth factor-reduced matrigel (BD Biosciences). For colony outgrowth assays, 2000 cells were plated into 50 μl growth factor-reduced matrigel in 96-well plates and incubated for 7 days.
Plasmids and constructs eIF4E and eIF4E S209A constructs were described. 10,24 pcDNA3.1-FLAGeIF4E
WT was described 79 and used to obtain pcDNA3.1-FLAG-eIF4E S209A by quick-change PCR mutagenesis with the following primers:
5′-GACACAGCTACTAAGGCAGGCTCCACCACTAAAAATAGGTTTGTTGTTTA AGAAG-3′ and 5′-GTGGTGGAGCCTGCCTTAGTAGCTGTGTCTGCGTGGGACTG ATAACC-3′.
MMP-3 complementary DNA was obtained from Origene (Rockville, MD, USA) in pCMV6-XL4 and cloned into pcDNA3.1 using the NotI restriction sites. pCDNA3.1-HA-SNAIL was obtained from Addgene (Cambridge, MA, USA).
Polysome profile analysis, RNA isolation and quantitative reverse transcription-PCR Polysome profile analysis was carried out as described. 78 RNA from each fraction was isolated using easy-BLUE kit (FroggaBio, Toronto, ON, Canada) and treated with DNaseTurbo (Life Technologies) according to the manufacturer's instructions. Reverse transcription-PCR of 100 ng RNA of each fraction was carried out using SuperScript III First-Strand Synthesis System (Life Technologies). quantitative PCRs were carried out in a Mastercycler Realplex 2 (Eppendorf, Hamburg, Germany) system using iQ Sybr green Supermix (Bio-Rad) according to the manufacturer's instructions.
Bioinformatics analysis
To identify genes whose translation is sensitive to eIF4E phosphorylation we reanalyzed a previously generated dataset. 24 To enable analysis of differential translation using the anota algorithm, 80 we simulated a third replicate as described. 81 This analysis results in an increase in false positives, but provides a ranking of genes that can be used for robust analysis, such as analysis of overrepresentation of genes belonging to specific pathways. To identify differential translation we used anota with Figure 8 . Model: Non-canonical TGFβ signaling promotes the phospho-eIF4E (p-eIF4E) dependent translation of EMT/metastasispromoting transcripts, which are induced transcriptionally by the canonical SMAD pathway.
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